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The effect of genetic variants in the thrombin activatable
fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot
lysis time and the risk of venous thrombosis
Thrombin activatable fibrinolysis inhibitor (TAFI) is an
important inhibitor of fibrinolysis, which acts by inhibiting
the assembly of fibrinolytic factors on the fibrin surface (Bajzar
et al, 1996). Recently, it was shown that elevated TAFI antigen
levels are a mild risk factor for the occurrence of deep venous
thrombosis (DVT) (van Tilburg et al, 2000). TAFI levels
increase with age, mainly in women, and are elevated in oral
contraceptive users (van Tilburg et al, 2000).
Thrombin activatable fibrinolysis inhibitor levels are also
genetically determined and the )438 G/A TAFI single nucleo-
tide polymorphism (SNP) in the promoter region (Henry et al,
2001) and the 505 G/A SNP (Henry et al, 2001) and 1040 C/T
SNP in the coding region (Brouwers et al, 2001) are associated
with TAFI plasma antigen levels. The )438 G/A polymorphism
was reported to be associated with an increased risk of
developing venous thrombosis (Franco et al, 2001; Zidane
et al, 2003).
Recently, the effect of TAFI polymorphisms on TAFI antigen
levels has been debated since variable antibody reactivity
towards TAFI isoforms (in particular the 1040C/T polymor-
phism) leads to artefacts in TAFI antigen levels (Guimaraes
et al, 2004).
We analysed data from the Leiden Thrombophilia Study
(LETS) to assess the risk of developing DVT associated with
three SNPs of the TAFI gene [)438 G/A (rs no. 2146881), 505
A/G (rs no. 3742264) and 1040 C/T (rs no. 1926447)] in 471
patients with a first DVT, aged 18–70 years (patients with
cancer excluded) and 472 sex- and age-matched control
subjects. The risk of venous thrombosis associated with each
polymorphism was expressed as an odds ratio (OR) with a
corresponding 95% confidence interval (95% CI). In addition,
the TAFI multilocus haplotype effects on TAFI antigen levels
were estimated using weighted linear regression as described by
Tanck et al (2003). After modification of the method,
(weighted) logistic regression was used to investigate the
association between TAFI haplotypes and the risk of throm-
bosis. Furthermore, the effect of the three SNPs on the TAFI
antigen levels and clot lysis time was assessed in the control
group. TAFI antigen levels were measured by the Laurell
method, which is insensitive to TAFI genotype artefacts (van
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Thrombin activatable fibrinolysis inhibitor (TAFI) is an important inhibitor
of fibrinolysis. High TAFI antigen levels are associated with an increased risk
of deep venous thrombosis (DVT). Because TAFI levels are partly determined
genetically, we assessed the association between three TAFI gene
polymorphisms ()438 G/A, 505 A/G and 1040 C/T), TAFI antigen levels
and clot lysis times and the risk of DVT. Carriers of the 505G allele, which is
associated with lower TAFI antigen levels than the 505A allele, showed an
increased risk of DVT. This indicates that the relationship between TAFI and
venous thrombosis is more complex than previously suggested.
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Tilburg et al, 2000; Guimaraes et al, 2004). Moreover, TAFI
antigen levels may not represent the functional activity of
TAFI, which is measured by the rate of cleavage of a small
substrate after activation with thrombin thrombomodulin
(Zorio et al, 2003). Mosnier et al (1998) described a plasma
based clot lysis assay, which was initially developed to study
TAFI-related processes. It was shown that clot lysis times were
associated with both TAFI antigen and activity levels in a
group of 20 healthy volunteers. However, recently we showed
in a much larger group of healthy subjects (n ¼ 469), which is
the control group of the study we report on here, that the
association between the clot lysis time and TAFI antigen levels
was, at most, very weak (0Æ188 increase in clot lysis time (in
min) per 1 U/dl increase in TAFI, after age-adjustment)
(Lisman et al, 2005).
In the total study population, 403 (43%) were men, 540
(57%) women and the mean age in patients and control
subjects was 45Æ0 years (range 15–69 years) and 44Æ7 years
(15–72 years), respectively. The distribution of the three TAFI
SNPs in the control subjects did not deviate from Hardy–
Weinberg equilibrium.
All three SNP were associated with TAFI antigen levels,
which was more pronounced in homozygotes than in hetero-
zygotes (Table I). For the )G438A and C1040T variants, the
rare alleles were associated with lower levels than common
alleles, while for the G505A the rare allele was associated with
higher TAFI levels than the common allele. The effect on TAFI
levels was most striking for the 505 genotypes, with 17% higher
TAFI levels in carriers of 505AA than 505GG. These findings
are in agreement with earlier observations (Brouwers et al,
2001, 2003).
These associations between genotypes and levels would
predict an increased risk of thrombosis for the 505A, )438G
and 1040C allele. A clear and graded relationship between
genotype and risk of thrombosis was, however, only observed
for the 505A genotype, with lower risks for the rare A-allele.
Because there is a high level of linkage disequilibrium between
these TAFI polymorphisms, haplotype analysis was necessary
to analyse the effects of a single polymorphism while excluding
the effects of associated polymorphisms. Haplotype analysis
confirmed the association of the G505A polymorphism and
risk of venous thrombosis. The 505G allele was associated with
a mildly increased risk of venous thrombosis [OR 1Æ3 (1Æ0–1Æ6);
Fig 1B]. The 505G allele was associated with reduced TAFI
levels, both by the single genotype and by the haplotype
analysis (Fig 1A). The analysis, therefore, suggested that a
direct, functional role is more likely for the G505A poly-
morphism than for the other studied TAFI polymorphisms.
We have now found a reduced risk of DVT with the allele that
is associated with higher TAFI levels and lower clot lysis times,
which was in contrast to the hypothesis on which we based on
our previous findings (van Tilburg et al, 2000). A possible
explanation, besides chance findings, is that moderately
elevated TAFI antigen levels do not alter the risk of venous
thrombosis. Previously, we only found an increased risk when
TAFI antigen levels exceeded 122 U/dl (van Tilburg et al,
2000), whereas none of the genotypes we studied were
associated with such high levels of TAFI antigen. However, it
may also be that the elevated levels of TAFI we previously
observed in patients who had suffered venous thrombosis
compared with healthy controls were a consequence rather
than a cause of thrombosis.
All three SNPs were associated with TAFI antigen levels, but
only a relationship between TAFI 505A polymorphism and clot
lysis times was observed (Table I). We have recently shown in
these same individuals that TAFI antigen levels and clot lysis
times were only weakly associated (Lisman et al, 2005). The
present study showed an increased risk of DVT in carriers of













GG 240 (51Æ0) 257 (54Æ4) 1 110 (108–111) 59Æ6 (58Æ4–60Æ8)
AG 202 (42Æ9) 185 (39Æ2) 1Æ17 (0Æ89–1Æ53) 104 (102–106) 63Æ0 (61Æ3–64Æ7)
AA 29 (6Æ1) 30 (6Æ4) 1Æ04 (0Æ60–1Æ78) 96 (92–100) 61Æ5 (56Æ0–67Æ1)
505
GG 236 (50Æ1) 211 (44Æ7) 1 102 (101–103) 61Æ6 (59Æ9–63Æ2)
AG 198 (42Æ0) 210 (44Æ5) 0Æ84 (0Æ64–1Æ10) 108 (107–110) 60Æ7 (59Æ4–62Æ0)
AA 37 (7Æ9) 51 (10Æ8) 0Æ65 (0Æ41–1Æ03) 119 (115–122) 60Æ3 (56Æ9–63Æ6)
1040
CC 219 (46Æ5) 215 (45Æ6) 1 110 (108–111) 59Æ1 (57Æ8–60Æ3)
CT 218 (46Æ3) 212 (44Æ9) 1Æ01 (0Æ77–1Æ32) 105 (104–107) 62Æ8 (61Æ2–64Æ3)
TT 34 (7Æ2) 45 (9Æ5) 0Æ74 (0Æ46–1Æ20) 98 (95–102) 62Æ3 (58Æ0–66Æ6)
CLT, clot lysis time.
Linear regression analysis showed a mean decrease of TAFI of 6Æ3 U/dl (95% CI 4Æ5–8Æ0) per additional A-allele at )438, a mean increase of 7Æ6 U/dl
(95% CI 6Æ1–9Æ2) per additional A-allele at 505, and a decrease of 5Æ2 U/dl (95% CI 3Æ5–6Æ8) at 1040.
*TAFI and CLT levels in control subjects.
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the 505G allele. The 505 G-allele is associated with low TAFI
antigen levels, which indicates that there is complex relation-
ship between TAFI and the risk of venous thrombosis.
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B
Fig 1. (A) The effect of TAFI haplotypes on plasma TAFI antigen levels
in the LETS study population (levels are expressed as mean and 95%
CI). (B) The effect of TAFI haplotypes on risk of venous thrombosis in
patients vs controls expressed as odds ratios. The alleles in the haplotype
are given in the following polymorphism order: )438G/A. 505G/A
(Ala147Thr) and 1040C/T (Thr325Ile). GAC as reference.
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